Abstract - 603777 Disclosed are N-[{ [1-(6-alkoxy-1,3-benzothiazol-2-yl)piperidin-4-yl]oxy} -alkyl]acetamide derivatives as represented by the general formula (I), wherein R1 is (1) a group represented by the formula: COR2 or (2) a 5-membered aromatic heterocyclic group optionally substituted by 1 to 3 alkyl substituents R3 is an alkyl group optionally substituted by 1 to 3 halogen atoms R4 is a hydrogen atom X is O or CH2 ring A is a 4- to 6-membered nitrogen-containing non-aromatic heterocycle or cyclohexane wherein the heterocycle is optionally crosslinked ring P and ring Q are condensed to form a 1,3-benzoxazole, a benzo[b]furan, a 1,3-benzothiazole, a [1,3]oxazolo[5,4-b]pyridine, a [1,3]oxazolo[5,4-c]pyridine, a [1,3]oxazolo[4,5-b]pyridine, a imidazo[1,5-a]pyridine, an indazol or benzotriazole, in each of which, ring Q is optionally substituted by 1 to 3 halogen atoms and R6 is an alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom or cycloalkyl or a salt thereof. Also disclosed are compounds such as N-[(1S)-2-({ 1-[6-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl} oxy)-1-methylethyl]acetamide, N-[(1S)-2-({ 1-[5-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl} oxy)-1-methylethyl]acetamide, N-[(1S)-3-{ 1-[6-(cyclopropylmethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl} -1-methylpropyl]acetamide, N-[(1S)-2-({ 1-[6-(2-cyclopropylethoxy)-1,3-benzoxazol-2-yl]piperidin-4-yl} oxy)-1-methylethyl]acetamide, N-[(1S)-1-methyl-2-({ 1-[6-(2,2,2-trifluoroethoxy)-1,3-benzothiazol-2-yl]piperidin-4-yl} oxy)ethyl]acetamide, N-[2-({ trans-4-[6-(cyclopropylmethoxy)-1-benzofuran-2-yl]cyclohexyl} oxy)-1-methylethyl]acetamide and N-[(1S)-2-({ trans-4-[6-(2-cyclopropylethoxy)-2H-indazol-2-yl]cyclohexyl} oxy)-1-methylethyl]acetamide. Further disclosed is a medicament which comprises a compound or salt as defined above, which is an acetyl-CoA carboxylase inhibitor, for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlip
